Novo Nordisk A/S (NYSE:NVO) Holdings Decreased by Harrington Investments INC

Harrington Investments INC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO – Get Rating) by 0.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,738 shares of the company’s stock after selling 127 shares during the quarter. Novo Nordisk A/S comprises about 1.7% of Harrington Investments INC’s investment portfolio, making the stock its 24th largest holding. Harrington Investments INC’s holdings in Novo Nordisk A/S were worth $2,401,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Worth Asset Management LLC bought a new stake in shares of Novo Nordisk A/S during the first quarter valued at about $32,000. Financial Management Professionals Inc. raised its stake in shares of Novo Nordisk A/S by 95.0% during the third quarter. Financial Management Professionals Inc. now owns 312 shares of the company’s stock valued at $31,000 after purchasing an additional 152 shares in the last quarter. MADDEN SECURITIES Corp bought a new stake in Novo Nordisk A/S in the fourth quarter worth about $46,000. MinichMacGregor Wealth Management LLC bought a new stake in Novo Nordisk A/S in the fourth quarter worth about $48,000. Finally, Penserra Capital Management LLC bought a new stake in Novo Nordisk A/S in the third quarter worth about $36,000. 6.09% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Up 0.4 %

NVO traded up $0.55 during trading on Friday, reaching $139.44. The company had a trading volume of 1,727,274 shares, compared to its average volume of 1,292,450. The firm’s 50-day simple moving average is $139.97 and its 200 day simple moving average is $123.57. The company has a market cap of $315.55 billion, a price-to-earnings ratio of 40.18, a PEG ratio of 1.47 and a beta of 0.47. Novo Nordisk A/S has a 12-month low of $95.02 and a 12-month high of $145.94. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.69 and a current ratio of 0.89.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 4th. Investors of record on Monday, March 27th will be paid a $1.1887 dividend. The ex-dividend date of this dividend is Friday, March 24th. This represents a yield of 0.8%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.58. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 23.34%.

Analyst Upgrades and Downgrades

NVO has been the topic of several research reports. Cowen boosted their price target on shares of Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. Cowen boosted their price target on shares of Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. JPMorgan Chase & Co. boosted their price target on shares of Novo Nordisk A/S from 925.00 to 1,100.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 3rd. Finally, StockNews.com initiated coverage on shares of Novo Nordisk A/S in a research report on Thursday. They issued a “strong-buy” rating on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $697.78.

Novo Nordisk A/S Company Profile

(Get Rating)

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.